Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.25 USD | 0.00% | -1.22% | +6.61% |
May. 16 | Aileron Therapeutics, Inc. Announces Chief Financial Officer Changes | CI |
May. 16 | Aileron Therapeutics, Inc. Announces Executive Changes | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 70.17M |
---|---|---|---|---|---|
Net income 2024 * | -22M | Net income 2025 * | -24M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.62
x | P/E ratio 2025 * |
-2.34
x | Employees | 15 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.51% |
Latest transcript on Aileron Therapeutics, Inc.
1 day | +0.62% | ||
1 week | -1.52% | ||
Current month | +1.56% | ||
1 month | -14.92% | ||
3 months | -38.10% | ||
6 months | +31.05% | ||
Current year | +6.61% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
David Annis
CTO | Chief Tech/Sci/R&D Officer | 51 | 07-10-31 |
Director/Board Member | 53 | 14-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 19-06-18 | |
Alan Musso
BRD | Director/Board Member | 62 | 23-10-30 |
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-13 | 3.25 | 0.00% | 67 958 |
24-06-12 | 3.25 | +0.62% | 140,642 |
24-06-11 | 3.23 | +1.57% | 79,299 |
24-06-10 | 3.18 | -1.85% | 74,854 |
24-06-07 | 3.24 | -1.52% | 11,401 |
Delayed Quote Nasdaq, June 12, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.61% | 70.17M | |
+16.93% | 123B | |
+17.01% | 111B | |
-7.23% | 23.63B | |
+2.53% | 22.58B | |
-14.29% | 17.26B | |
-6.79% | 17.6B | |
-37.63% | 17.61B | |
+2.17% | 13.55B | |
+24.42% | 11.34B |
- Stock Market
- Equities
- ALRN Stock